Mpox (Monkeypox) Vaccine Triggers Equally Strong Immune Response in Smaller Than Usual Doses and in People With or Without HIV
Retrieved on:
Thursday, December 14, 2023
World Health Organization, NYU Langone Health, Mental Hygiene, Research, National Institutes of Health, New Yorker, Coinfection, Risk, Congo, Vaccination, Infection, Death, FDA, Division, Mpox, CD4, Master of Science, NYU, HIV, CDC, Antibody, Doctor of Philosophy, Skin, Jeff Kottkamp, Injection, Face, Immunoglobulin G, Smallpox, Democratic republic, Vaccine, Pharmaceutical industry, MD
Because of limited space between skin layers, intradermal injections can only accommodate small doses, while larger doses generally require subcutaneous injections.
Key Points:
- Because of limited space between skin layers, intradermal injections can only accommodate small doses, while larger doses generally require subcutaneous injections.
- The smaller doses, about one-fifth of the usual full dose and spread out by as long as three months, were designed to stretch the short supply of vaccine available after an outbreak in May 2022.
- The IgG antibodies were detected in some cases more than six months after a second and final dose of the vaccine.
- The mpox vaccine is now routinely recommended by the Centers for Disease Control and Prevention (CDC) for people at risk.